Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Current Trends in Immunology   Volumes    Volume 23 
The efficacy of a microvesicle-based vaccine in eliciting a humoral immune response against orthohantavirus nucleocapsid peptides
L. Shkair, E. E. Garanina, A. A. Rizvanov
Pages: 53 - 67
Number of pages: 15
Current Trends in Immunology
Volume 23 

Copyright © 2022 Research Trends. All rights reserved

Orthohantaviruses are rodent-borne pathogens that cause hemorrhagic fever with renal syndrome disease (HFRS) in Eurasia. The highest incidence of orthohantavirus infection is documented in the Volga region of Russia. Puumala orthohantavirus was identified as the causative agent. Life-threatening complications were diagnosed in some HFRS cases leading to prolonged recovery periods or even fatal outcomes. There are limited options for HFRS prevention in Russia. Identifying the most immunogenic epitopes of structural protein is the first stage of vaccine development. This study aimed to evaluate the immunogenicity of a microvesicle (MV)-based vaccine carrying Pummala virus nucleocapsid proteins (PUUV N) or a combination of nucleocapsid and glycoproteins (PUUV N-Gn/Gc). We found the most immunogenic PUUV N peptides after vaccination. Also, we demonstrated that the MV-based vaccine carrying PUUV N or PUUV N-Gn/Gc could elicit cross-protection immunity against N peptides of other orthohantavirus strains.
Buy this Article


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms